Cargando…

Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response

Thromboembolic events were described in patients with Chagas disease without cardiomyopathy. We aim to confirm if there is a hypercoagulable state in these patients and to determine if there is an early normalization of hemostasis factors after antiparasitic treatment. Ninety-nine individuals from C...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinazo, Maria-Jesus, Posada, Elizabeth de Jesus, Izquierdo, Luis, Tassies, Dolors, Marques, Alexandre-Ferreira, de Lazzari, Elisa, Aldasoro, Edelweiss, Muñoz, Jose, Abras, Alba, Tebar, Silvia, Gallego, Montserrat, de Almeida, Igor Correia, Reverter, Joan-Carles, Gascon, Joaquim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700971/
https://www.ncbi.nlm.nih.gov/pubmed/26727000
http://dx.doi.org/10.1371/journal.pntd.0004269
_version_ 1782408409503498240
author Pinazo, Maria-Jesus
Posada, Elizabeth de Jesus
Izquierdo, Luis
Tassies, Dolors
Marques, Alexandre-Ferreira
de Lazzari, Elisa
Aldasoro, Edelweiss
Muñoz, Jose
Abras, Alba
Tebar, Silvia
Gallego, Montserrat
de Almeida, Igor Correia
Reverter, Joan-Carles
Gascon, Joaquim
author_facet Pinazo, Maria-Jesus
Posada, Elizabeth de Jesus
Izquierdo, Luis
Tassies, Dolors
Marques, Alexandre-Ferreira
de Lazzari, Elisa
Aldasoro, Edelweiss
Muñoz, Jose
Abras, Alba
Tebar, Silvia
Gallego, Montserrat
de Almeida, Igor Correia
Reverter, Joan-Carles
Gascon, Joaquim
author_sort Pinazo, Maria-Jesus
collection PubMed
description Thromboembolic events were described in patients with Chagas disease without cardiomyopathy. We aim to confirm if there is a hypercoagulable state in these patients and to determine if there is an early normalization of hemostasis factors after antiparasitic treatment. Ninety-nine individuals from Chagas disease-endemic areas were classified in two groups: G1, with T.cruzi infection (n = 56); G2, healthy individuals (n = 43). Twenty-four hemostasis factors were measured at baseline. G1 patients treated with benznidazole were followed for 36 months, recording clinical parameters and performance of conventional serology, chemiluminescent enzyme-linked immunosorbent assay (trypomastigote-derived glycosylphosphatidylinositol-anchored mucins), quantitative polymerase chain reaction, and hemostasis tests every 6-month visits. Prothrombin fragment 1+2 (F1+2) and endogenous thrombin potential (ETP) were abnormally expressed in 77% and 50% of infected patients at baseline but returned to and remained at normal levels shortly after treatment in 76% and 96% of cases, respectively. Plasmin-antiplasmin complexes (PAP) were altered before treatment in 32% of G1 patients but normalized in 94% of cases several months after treatment. None of the patients with normal F1+2 values during follow-up had a positive qRT-PCR result, but 3/24 patients (13%) with normal ETP values did. In a percentage of chronic T. cruzi infected patients treated with benznidazole, altered coagulation markers returned into normal levels. F1+2, ETP and PAP could be useful markers for assessing sustained response to benznidazole.
format Online
Article
Text
id pubmed-4700971
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-47009712016-01-15 Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response Pinazo, Maria-Jesus Posada, Elizabeth de Jesus Izquierdo, Luis Tassies, Dolors Marques, Alexandre-Ferreira de Lazzari, Elisa Aldasoro, Edelweiss Muñoz, Jose Abras, Alba Tebar, Silvia Gallego, Montserrat de Almeida, Igor Correia Reverter, Joan-Carles Gascon, Joaquim PLoS Negl Trop Dis Research Article Thromboembolic events were described in patients with Chagas disease without cardiomyopathy. We aim to confirm if there is a hypercoagulable state in these patients and to determine if there is an early normalization of hemostasis factors after antiparasitic treatment. Ninety-nine individuals from Chagas disease-endemic areas were classified in two groups: G1, with T.cruzi infection (n = 56); G2, healthy individuals (n = 43). Twenty-four hemostasis factors were measured at baseline. G1 patients treated with benznidazole were followed for 36 months, recording clinical parameters and performance of conventional serology, chemiluminescent enzyme-linked immunosorbent assay (trypomastigote-derived glycosylphosphatidylinositol-anchored mucins), quantitative polymerase chain reaction, and hemostasis tests every 6-month visits. Prothrombin fragment 1+2 (F1+2) and endogenous thrombin potential (ETP) were abnormally expressed in 77% and 50% of infected patients at baseline but returned to and remained at normal levels shortly after treatment in 76% and 96% of cases, respectively. Plasmin-antiplasmin complexes (PAP) were altered before treatment in 32% of G1 patients but normalized in 94% of cases several months after treatment. None of the patients with normal F1+2 values during follow-up had a positive qRT-PCR result, but 3/24 patients (13%) with normal ETP values did. In a percentage of chronic T. cruzi infected patients treated with benznidazole, altered coagulation markers returned into normal levels. F1+2, ETP and PAP could be useful markers for assessing sustained response to benznidazole. Public Library of Science 2016-01-04 /pmc/articles/PMC4700971/ /pubmed/26727000 http://dx.doi.org/10.1371/journal.pntd.0004269 Text en © 2016 Pinazo et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
spellingShingle Research Article
Pinazo, Maria-Jesus
Posada, Elizabeth de Jesus
Izquierdo, Luis
Tassies, Dolors
Marques, Alexandre-Ferreira
de Lazzari, Elisa
Aldasoro, Edelweiss
Muñoz, Jose
Abras, Alba
Tebar, Silvia
Gallego, Montserrat
de Almeida, Igor Correia
Reverter, Joan-Carles
Gascon, Joaquim
Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response
title Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response
title_full Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response
title_fullStr Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response
title_full_unstemmed Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response
title_short Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response
title_sort altered hypercoagulability factors in patients with chronic chagas disease: potential biomarkers of therapeutic response
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700971/
https://www.ncbi.nlm.nih.gov/pubmed/26727000
http://dx.doi.org/10.1371/journal.pntd.0004269
work_keys_str_mv AT pinazomariajesus alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse
AT posadaelizabethdejesus alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse
AT izquierdoluis alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse
AT tassiesdolors alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse
AT marquesalexandreferreira alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse
AT delazzarielisa alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse
AT aldasoroedelweiss alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse
AT munozjose alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse
AT abrasalba alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse
AT tebarsilvia alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse
AT gallegomontserrat alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse
AT dealmeidaigorcorreia alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse
AT reverterjoancarles alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse
AT gasconjoaquim alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse